Drug Profile
Research programme: adenosine A2A/A1 selective antagonists - Domain Therapeutics/CleveXel Pharma
Alternative Names: CVXL-0069; DT 1133; DT0926; FP 0692; FP 1133Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Faust Pharmaceuticals
- Developer CleveXel Pharma; Domain Therapeutics
- Class Benzoxazoles; Small molecules
- Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Drug-induced dyskinesia; Parkinson's disease
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in France (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in France (PO)
- 08 Oct 2014 Preclinical development is ongoing in France